meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)
3
mHCC - 1st line (L1)
10
mHCC - 2nd line (L2)
2
lung cancer : non small cell (NSCLC)
5
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab
atezolizumab plus cabozantinib
camrelizumab based treatment
durvalumab based treatment
durvalumab plus bevacizumab
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus lenvatinib
sintilimab based treatment
sintilimab
Tislelizumab
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
nivolumab plus ipilimumab plus SoC
VEGF(R) inhibitor
bevacizumab based treatment
bevacizumab
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs atezolizumab based treatment
vs atezolizumab plus bevacizumab
vs nivolumab based treatment
vs nivolumab alone
vs non active control
vs no additional treatment
vs placebo
vs VEGF(R) inhibitor
vs lenvatinib
vs sorafenib
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
pembrolizumab alone
title
pembrolizumab plus lenvatinib
title
lenvatinib
title
placebo
title
LEAP 002, 2023 NCT03713593 mHCC - 1st line (L1) 395/399
KEYNOTE-240, 2020 NCT02702401 mHCC - 2nd line (L2) 278/135
KEYNOTE-394, 2022 NCT03062358 mHCC - 2nd line (L2) 300/153
Pathology:
mHCC - 1st line (L1);
mHCC - 2nd line (L2);
mHCC - 1st line (L1)
mHCC - 2nd line (L2)
LEAP 002, 2023
KEYNOTE-240, 2020
KEYNOTE-394, 2022
pembrolizumab alone
2
T1
T1
pembrolizumab plus lenvatinib
1
T1
lenvatinib
0
T0
placebo
0
T0
T0